BioSyent (BIOY.F) Stock Overview
Acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for BIOY.F from our risk checks.
BIOY.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
BioSyent Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$11.50 |
| 52 Week High | CA$12.00 |
| 52 Week Low | CA$6.49 |
| Beta | 0.60 |
| 1 Month Change | 12.55% |
| 3 Month Change | 31.04% |
| 1 Year Change | 53.13% |
| 3 Year Change | 121.15% |
| 5 Year Change | 99.65% |
| Change since IPO | 2,013.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOY.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.2% | -1.0% | -0.6% |
| 1Y | 53.1% | 25.5% | 21.7% |
Return vs Industry: BIOY.F exceeded the US Pharmaceuticals industry which returned 25.5% over the past year.
Return vs Market: BIOY.F exceeded the US Market which returned 21.7% over the past year.
Price Volatility
| BIOY.F volatility | |
|---|---|
| BIOY.F Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BIOY.F has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BIOY.F's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | René Goehrum | www.biosyent.com |
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
BioSyent Inc. Fundamentals Summary
| BIOY.F fundamental statistics | |
|---|---|
| Market cap | US$131.18m |
| Earnings (TTM) | US$6.36m |
| Revenue (TTM) | US$31.05m |
Is BIOY.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOY.F income statement (TTM) | |
|---|---|
| Revenue | CA$42.18m |
| Cost of Revenue | CA$9.51m |
| Gross Profit | CA$32.67m |
| Other Expenses | CA$24.04m |
| Earnings | CA$8.63m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.75 |
| Gross Margin | 77.46% |
| Net Profit Margin | 20.47% |
| Debt/Equity Ratio | 0% |
How did BIOY.F perform over the long term?
See historical performance and comparisonDividends
Does BIOY.F pay a reliable dividends?
See BIOY.F dividend history and benchmarks| BioSyent dividend dates | |
|---|---|
| Ex Dividend Date | Feb 27 2026 |
| Dividend Pay Date | Mar 13 2026 |
| Days until Ex dividend | 13 days |
| Days until Dividend pay date | 1 day |
Does BIOY.F pay a reliable dividends?
See BIOY.F dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/11 02:11 |
| End of Day Share Price | 2026/03/11 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioSyent Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tania Armstrong-Whitworth | ATB Cormark Historical (Cormark Securities) |
| David Martin | Bloom Burton & Co. |
| Scott Curtis | Cantor Fitzgerald Canada Corporation |